G 
Gwo Xi Stem Cell Applied Technology Co 6704.TWO · TWD
Health Care · Taipei Exchange · 🇹🇼 Taiwan
20.15
+0.75%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in TWD, from our data supplier.
Revenue
TWD 187.0m
FY2019FY2025
Net income
−TWD 80.5m
FY2019FY2025
Free cash flow
−TWD 80.7m
FY2019FY2025
Shareholders' equity
TWD 580.4m
FY2019FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | TWD 187.0m | TWD 170.0m | TWD 141.2m | TWD 180.7m | TWD 242.8m | TWD 188.5m | TWD 176.7m |
| Research and development | TWD 115.5m | TWD 110.7m | TWD 108.2m | TWD 109.2m | TWD 95.1m | TWD 86.8m | TWD 93.1m |
| Operating income | −TWD 73.7m | −TWD 75.9m | −TWD 94.0m | −TWD 115.3m | −TWD 99.4m | −TWD 74.4m | −TWD 83.2m |
| Net income | −TWD 80.5m | −TWD 83.3m | −TWD 88.1m | −TWD 112.1m | −TWD 105.6m | −TWD 84.2m | −TWD 76.9m |
| Diluted earnings per share | -0.84 | -0.87 | -0.97 | -1.28 | -1.27 | -0.96 | -1.01 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Total assets | TWD 978.1m | TWD 1.06bn | TWD 1.23bn | TWD 1.04bn | TWD 1.09bn | TWD 1.18bn | TWD 1.06bn |
| Cash and short-term investments | — | TWD 282.8m | TWD 402.5m | TWD 141.0m | TWD 118.6m | TWD 178.0m | TWD 191.7m |
| Total liabilities | TWD 397.7m | TWD 400.8m | TWD 481.5m | TWD 534.6m | TWD 595.7m | TWD 577.5m | TWD 466.1m |
| Debt | TWD 243.3m | TWD 364.5m | TWD 417.0m | TWD 499.1m | TWD 544.6m | TWD 514.8m | TWD 420.9m |
| Shareholders' equity | TWD 580.4m | TWD 660.9m | TWD 744.2m | TWD 510.3m | TWD 482.4m | TWD 590.6m | TWD 548.0m |
| Shares outstanding | 96m | 96m | 91m | 88m | 83m | 88m | 76m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Cash from operations | −TWD 28.0m | −TWD 52.3m | −TWD 4.9m | −TWD 64.2m | −TWD 29.1m | −TWD 72.6m | −TWD 82.9m |
| Capital spending | −TWD 52.7m | −TWD 23.0m | −TWD 12.9m | −TWD 17.7m | −TWD 43.2m | −TWD 111.7m | −TWD 224.7m |
| Free cash flow | −TWD 80.7m | −TWD 75.3m | −TWD 17.8m | −TWD 81.9m | −TWD 72.3m | −TWD 184.3m | −TWD 307.6m |
Latest quarters
By quarter end
| Jun 2025 | Dec 2024 | Jun 2024 | Dec 2023 | Jun 2023 | Dec 2022 | Jun 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | TWD 94.5m | TWD 90.4m | TWD 79.6m | TWD 70.9m | TWD 70.3m | TWD 90.2m | TWD 90.5m | TWD 121.4m |
| Operating income | −TWD 31.6m | −TWD 31.3m | −TWD 44.7m | −TWD 51.7m | −TWD 42.2m | −TWD 52.6m | −TWD 55.9m | −TWD 48.6m |
| Net income | −TWD 34.9m | −TWD 35.2m | −TWD 48.1m | −TWD 55.5m | −TWD 32.5m | −TWD 49.9m | −TWD 62.2m | −TWD 52.8m |
| Diluted earnings per share | -0.36 | -0.37 | -0.50 | -0.61 | -0.36 | -0.57 | -0.71 | -0.64 |
| Cash from operations | −TWD 19.0m | −TWD 21.0m | −TWD 26.0m | −TWD 9.0m | TWD 5.0m | −TWD 46.0m | — | −TWD 14.0m |
| Capital spending | −TWD 32.0m | −TWD 7.0m | −TWD 15.0m | −TWD 12.0m | — | −TWD 10.0m | — | −TWD 21.0m |
| Free cash flow | −TWD 51.0m | −TWD 28.0m | −TWD 41.0m | −TWD 21.0m | — | −TWD 56.0m | — | −TWD 35.0m |
| Total assets | TWD 1.01bn | TWD 1.06bn | TWD 1.14bn | TWD 1.23bn | TWD 991.6m | TWD 1.04bn | — | TWD 1.09bn |
| Cash and short-term investments | TWD 211.8m | TWD 282.8m | TWD 329.7m | TWD 402.5m | TWD 151.4m | TWD 141.0m | — | TWD 118.6m |
| Debt | TWD 306.0m | TWD 323.1m | TWD 342.6m | TWD 51.0m | TWD 59.5m | TWD 71.2m | — | TWD 84.4m |
| Shareholders' equity | TWD 626.0m | TWD 660.9m | TWD 696.1m | TWD 744.2m | TWD 477.8m | TWD 510.3m | — | TWD 482.4m |
Financial ratios
Data as of 28 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Operating margin | -37.8% | -42.3% | -53.0% | -60.3% | -39.2% | -37.4% |
| Net margin | -43.1% | -49.0% | -62.4% | -62.1% | -43.5% | -44.7% |
| Return on equity | -13.9% | -12.6% | -11.8% | -22.0% | -21.9% | -14.3% |
| Return on assets | -8.2% | -7.8% | -7.2% | -10.7% | -9.7% | -7.2% |
| Free cash flow yield | 1.2% | -1.4% | 0.4% | -2.4% | 0.8% | 2.1% |
| Revenue growth | 10.0% | 20.4% | -21.9% | -25.6% | 28.8% | 6.7% |
| Earnings growth | -3.4% | -5.4% | -21.4% | 6.2% | 25.4% | 9.5% |
| Current ratio | 1.98x | 3.94x | 3.67x | 1.88x | 1.31x | 2.53x |
| Debt to equity | 0.42x | 0.49x | 0.50x | 0.88x | 1.01x | 0.08x |
| Equity ratio | 59.3% | 62.3% | 60.7% | 48.8% | 44.3% | 50.2% |
| Interest coverage | -7.19x | -6.29x | -6.05x | -55.66x | -56.94x | -52.61x |
| R&D as a share of sales | 61.8% | 65.1% | 76.6% | 60.4% | 39.2% | 46.1% |
| Buybacks as a share of market value | 0.0% | -5.1% | -3.8% | -6.0% | 5.5% | -15.2% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 1.2% | -0.2% | — |
| Operating income | -13.9% | -0.2% | — |
| Net income | -10.4% | -0.9% | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Operating margin | -41.9% | -52.9% | -48.0% | — |
| Net margin | -45.9% | -53.6% | -49.9% | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Price to earnings | -32.2 | -31.8 | -37.6 |
| Price to sales | 13.8 | 15.6 | 23.5 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.